An advisory panel to the US Food and Drug Administration (FDA) voted unanimously to recommend approval of Moderna’s investigational mRNA-based seasonal influenza vaccine. The decision, announced by the Vaccines and Related Biological Products Advisory Committee (VRBPAC), signals a major step forward for the first mRNA flu shot, though final FDA authorization is still pending. The vote occurred against a backdrop of renewed political controversy surrounding mRNA technology.

Key takeaways

  • The FDA’s VRBPAC committee voted 12-to-0 in favor of Moderna’s mRNA flu vaccine.
  • If authorized, it would be the first mRNA-based flu vaccine on the US market.
  • Political tensions around mRNA technology, partly linked to COVID-19 vaccine debates, have shadowed the review process.
  • Final approval by the FDA typically follows advisory recommendations but is not guaranteed.

What the FDA panel decision means

The unanimous vote by VRBPAC is a strong endorsement of Moderna’s vaccine, which targets four influenza virus strains. According to reports from the meeting, panel members reviewed clinical trial data showing that the mRNA shot generated immune responses comparable or superior to existing inactivated flu vaccines. The recommendation covers adults aged 18 and older, though the committee discussed potential use in other age groups.

While advisory votes are not legally binding, the FDA usually follows its committees’ recommendations. A final decision could come within weeks. If approved, Moderna would join Sanofi and other manufacturers in the seasonal flu vaccine market, but with the unique distinction of using messenger RNA (mRNA) technology.

How the mRNA flu vaccine works

Like Moderna’s COVID-19 vaccine, the flu candidate uses mRNA molecules to instruct cells to produce a harmless piece of viral protein, prompting an immune response. Instead of growing the virus in eggs or cell cultures, mRNA vaccines can be designed and manufactured more quickly, which may allow better matching of circulating flu strains each season.

Moderna has stated that its mRNA platform could improve the accuracy of annual flu shots, which currently provide moderate protection due to difficulties in predicting the dominant strains. The company has also tested a combined COVID-19 and flu mRNA vaccine, though that product remains in development.

Political turbulence around mRNA technology

The VRBPAC meeting took place amid heightened political debate over mRNA vaccines. Critics, including some lawmakers, have questioned the long-term safety of the technology, which was rapidly deployed during the COVID-19 pandemic. The advisory panel members, however, focused on scientific evidence rather than political pressure, according to comments reported during the hearing.

Moderna and other mRNA developers have faced increased scrutiny from conservative groups and some state legislatures proposing restrictions on mRNA-based vaccines. Despite this, public health experts argue that the data supporting mRNA flu vaccines are robust and that approval could expand vaccine choices.

Next steps and potential impact

The FDA is expected to issue its final decision later this year. If authorized, the vaccine could be available for the 2025-2026 flu season. Moderna has already scaled up manufacturing capacity and says it can produce hundreds of millions of doses annually.

An approved mRNA flu vaccine would also strengthen Moderna’s position as a leading player in the broader mRNA vaccine space, beyond COVID-19. The company is currently testing mRNA vaccines for respiratory syncytial virus (RSV) and other infectious diseases.

Frequently Asked Questions

Is this vaccine safe and effective?

Clinical trial data reviewed by the FDA panel showed the mRNA flu vaccine produced immune responses comparable to or better than standard flu shots. The committee found no major safety concerns, though common side effects similar to other mRNA vaccines were noted, such as injection site pain and fatigue. Long-term follow-up studies are ongoing.

When could the vaccine be available to the public?

If the FDA grants authorization in the coming weeks, Moderna has indicated it could have doses ready for the next flu season, likely by the fall of 2025. Distribution would depend on recommendations from the Centers for Disease Control and Prevention (CDC).

How does the political environment affect the vaccine’s future?

Political opposition to mRNA technology may influence public acceptance, but the VRBPAC vote was based solely on scientific evidence. Some states have considered laws restricting mRNA vaccines, which could affect access if the shot is approved. However, federal health officials continue to back the safety and benefits of mRNA platforms based on available data.

This is an original report by Vital Signs Today, informed by reporting from Google News. Read the original source.

This article is for information only and is not medical advice. See our Medical Disclaimer.